Insight, China's Pharmaceutical Industry

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of...

Company Drug

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Fineline Cube Apr 8, 2026

Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig,...

Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026

Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German...

Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026

Biogen Inc. (NASDAQ: BIIB) announced a strategic licensing agreement with Alloy Therapeutics Inc., securing access...

Company Drug

Simcere’s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure

Fineline Cube Apr 8, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast...

Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026

Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests...

Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration...

Company Drug

GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio

Fineline Cube Apr 8, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China’s National Medical Products Administration (NMPA) has granted...

Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026

The Beijing Municipal Medical Insurance Bureau, in coordination with nine other government bureaus, has released...

Company Drug

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Fineline Cube Apr 7, 2026

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China’s National...

Company Drug

Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer

Fineline Cube Apr 7, 2026

Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China’s National...

Company Drug

Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response

Fineline Cube Apr 7, 2026

Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating...

Policy / Regulatory

China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized

Fineline Cube Apr 7, 2026

The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications...

Company Deals

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Fineline Cube Apr 7, 2026

Genesis MedTech, a Singapore-based medical device innovator, has acquired a controlling stake in Nanjing TUGE...

Company Deals

Sansure Biotech to Acquire WWHS Biotech, Gaining Exclusive Infrared Fluorescence Platform for Full-Scenario IVD Expansion

Fineline Cube Apr 7, 2026

Sansure Biotech Inc. (SHA: 688289), a leading Chinese in vitro diagnostics (IVD) company, has entered...

Company Deals

Conmind Medical Raises $29M in Series C to Advance Brain-Computer Interface and Cardio-Cerebral Integrated Care Platform

Fineline Cube Apr 7, 2026

Conmind Medical, a China-based brain science and medical technology platform, has secured RMB 200 million...

Company Deals Legal / IP

Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software

Fineline Cube Apr 4, 2026

Siemens Healthineers AG (ETR: SHL) has entered into a strategic collaboration with Ruijin Hospital, a...

Company Drug

Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent

Fineline Cube Apr 4, 2026

China’s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1...

Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Fineline Cube Apr 4, 2026

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China’s...

Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Fineline Cube Apr 4, 2026

Binhui Biopharmaceutical Co., Ltd. has submitted its initial public offering (IPO) prospectus to the Hong...

Insight, China's Pharmaceutical Industry

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Simcere’s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention

Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer

Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response

China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Sansure Biotech to Acquire WWHS Biotech, Gaining Exclusive Infrared Fluorescence Platform for Full-Scenario IVD Expansion

Conmind Medical Raises $29M in Series C to Advance Brain-Computer Interface and Cardio-Cerebral Integrated Care Platform

Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software

Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

You Missed

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors